E-LIB Suche - Ergebnisse für: Mesa, RA

1

Diastolic Blood Pressure and Cognitive Functioning: Differe..:

Mathew, A ; Mesa, RA ; Nahodyl, L...
American Journal of Alzheimer's Disease & Other Dementias®. 38 (2023) - p. 153331752311722 , 2023

Link: https://doi.org/10.1177/..

2

TRANSLATION AND LINGUISTIC VALIDATION OF THE MODIFIED MYELO..:

Eremenco, S ; Oko-osi, H ; Arnold, B...
Value in Health. 18 (2015) 7 - p. A471-A472 , 2015

Link: https://doi.org/10.1016/..

3

Symptomatic benefit of momelotinib in patients with myelofi..:

Mesa, RA ; Hudgens, S ; Floden, L...
doi:10.1002/cam4.5799. , 2024

Link: https://doi.org/10.1002/..

4

Ruxolitinib versus best available therapy for polycythemia ..:

Harrison, CN ; Nangalia, J ; Boucher, R...
doi:10.1200/JCO.22.01935. , 2024

Link: https://doi.org/10.1200/..

5

Ruxolitinib Versus Best Available Therapy for Polycythemia ..:

Harrison, CN ; Nangalia, J ; Boucher, R...
Journal of Clinical Oncology, 2023, pp. JCO2201935 -. , 2023

Link: https://repository.icr.a..

6

Diastolic blood pressure and cognitive functioning: differe..:

Mathew, A ; Mesa, RA ; Nahodyl, L...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398835/. , 2023

Link: http://www.ncbi.nlm.nih...

7

MOMENTUM: momelotinib vs danazol in patients with myelofibr..:

Verstovsek, S ; Chen, C-C ; Egyed, M...
doi:10.2217/fon-2020-1048. , 2021

Link: https://doi.org/10.2217/..

8

Association of clinical factors and recent anticancer thera..:

Grivas, P ; Khaki, AR ; Wise-Draper, TM...
qt49m429m0. , 2021

Link: https://escholarship.org..

9

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhi..:

Verstovsek, S ; Courby, S ; Griesshammer, M...
issn:0145-2126. , 2017

Link: http://hdl.handle.net/11..

10

Profile of pomalidomide and its potential in the treatment ..:

Gowin KL ; Mesa RA
http://www.dovepress.com/profile-of-pomalidomide-and-its-potential-in-the-treatment-of-myelofib-peer-reviewed-article-TCRM. , 2015

Link: https://doaj.org/article..

11

Management of cytopenias in patients with myelofibrosis tre..:

Verstovsek S ; Gotlib J ; Gupta V...
http://www.dovepress.com/management-of-cytopenias-in-patients-with-myelofibrosis-treated-with-r-a15309. , 2013

Link: https://doaj.org/article..

12

Ruxolitinib as an emerging treatment in myelofibrosis:

Emanuel RM ; Geyer HL ; Mesa RA
http://www.dovepress.com/ruxolitinib-as-an-emerging-treatment-in-myelofibrosis-a12419. , 2013

Link: https://doaj.org/article..

13

Recent developments in myelofibrosis:

Mesa RA ; Bogenberger JM ; Tibes R
http://www.dovepress.com/recent-developments-in-myelofibrosis-a10273. , 2012

Link: https://doaj.org/article..

14

5-Azacitidine has limited therapeutic activity in myelofibr..:

Mesa, RA ; Verstovsek, S ; Rivera, C...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721528/. , 2008

Link: http://www.ncbi.nlm.nih...

15

Bortezomib therapy in myelofibrosis: a phase II clinical tr..:

Mesa, RA ; Verstovsek, S ; Rivera, C...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167436/. , 2008

Link: http://www.ncbi.nlm.nih...